Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape.
Zhu F, Rajan S, Hayes CF, Kwong KY, Goncalves AR, Zemla AT, Lau EY, Zhang Y, Cai Y, Goforth JW, Landajuela M, Gilchuk P, Kierny M, Dippel A, Amofah B, Kaplan G, Cadevilla Peano V, Morehouse C, Sparklin B, Gopalakrishnan V, Tuffy KM, Nguyen A, Beloor J, Kijak G, Liu C, Dijokaite-Guraliuc A, Mongkolsapaya J, Screaton GR, Petersen BK, Desautels TA, Bennett D, Conti S, Segelke BW, Arrildt KT, Kaul S, Grzesiak EA, da Silva FL, Bates TW, Earnhart CG, Hopkins S, Sundaram S, Esser MT, Francica JR, Faissol DM; LLNL Generative Unconstrained Intelligent Drug Engineering (GUIDE) consortium.
Zhu F, et al. Among authors: hayes cf.
Sci Adv. 2025 Mar 28;11(13):eadu0718. doi: 10.1126/sciadv.adu0718. Epub 2025 Mar 28.
Sci Adv. 2025.
PMID: 40153503
Free PMC article.